2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-163348
    FXIIa-IN-4 98.87%
    FXIIa-IN-4 (compound 22) is a potent, selective human FXIIa inhibitor with the IC50 of 0.032 μM, 0.30 μM, ＞50 μM for FXIIa, thrombin and FXIa, respectively. FXIIa-IN-4 can be used for study of anticoagulant.
    FXIIa-IN-4
  • HY-17503R
    Metoprolol (Standard) 51384-51-1
    Metoprolol (Standard) is the analytical standard of Metoprolol. This product is intended for research and analytical applications. Metoprolol is an orally active, selective β1-adrenoceptor antagonist. Metoprolol shows anti-inflammation, antitumor and anti-angiogenic properties.
    Metoprolol (Standard)
  • HY-B0378A
    Moexipril hydrochloride 82586-52-5 98.95%
    Moexipril hydrochloride (RS-10085) is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila (hydrochloride). Moexipril hydrochloride exhibits antihypertensive and neuroprotective effects-.
    Moexipril hydrochloride
  • HY-B0428B
    Ozagrel hydrochloride 78712-43-3 99.68%
    Ozagrel hydrochloride (OKY-046 hydrochloride) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel hydrochloride is an antiplatelet agent, which selectively inhibits human platelet aggregationwith an IC50 of 53.12 μM.
    Ozagrel hydrochloride
  • HY-B0637S
    Bezafibrate-d6 1219802-74-0 ≥98.0%
    Bezafibrate-d6 is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
    Bezafibrate-d6
  • HY-B2209B
    Hydroxocobalamin acetate 22465-48-1 ≥98.0%
    Hydroxocobalamin acetate is an injectable natural vitamin B12. Hydroxocobalamin acetate binds to NO. Hydroxocobalamin acetate detoxifies Cyanide and NaSH. Hydroxocobalamin acetate reduces hypotension. Hydroxocobalamin acetate is used in research related to vitamin B12 deficiency, including pernicious anemia.
    Hydroxocobalamin acetate
  • HY-N0684S
    Vitamin K1-d7 1373049-34-3 ≥98.0%
    Vitamin K1-d7 is the deuterium labeled Vitamin K1. Vitamin K1 a naturally occurring vitamin required for blood coagulation and bone and vascular metabolism[1][2].
    Vitamin K1-d7
  • HY-P1839A
    Angiotensin I/II (1-5) (TFA) 99.52%
    Angiotensin I/II 1-5 TFA is a peptide that contains the amino acids 1-5, which is converted from Angiotensin I/II. Angiotensin I is formed by the action of renin on angiotensinogen. Angiotensin II is produced from angiotensin I. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy.
    Angiotensin I/II (1-5) (TFA)
  • HY-P3429A
    SAMβA TFA 99.13%
    SAMβA TFA is conjugated to the cell permeable peptide TAT47-57. SAMβA TFA, a rationally designed selective antagonist of Mfn1-βIIPKC association. SAMβA TFA is a selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats.
    SAMβA TFA
  • HY-P99546
    Trebananib 894356-79-7 ≥99.0%
    Trebananib (2xCon4C; AMG 386) is an Fc fusion peptibody that prevents Tie2 receptor activation through binding of both angiopoietin 1 (Ang1) and Ang2. Trebananib has anti-angiogenesis activity.
    Trebananib
  • HY-P99891
    Rovelizumab 339086-79-2
    Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke.
    Rovelizumab
  • HY-U00437
    Pz-1 1800505-64-9 ≥99.0%
    Pz-1 is a potent RET and VEGFR2 inhibitor with IC50s of less than 1 nM for both wild type kinases.
    Pz-1
  • HY-100795A
    Pirmenol hydrochloride 61477-94-9 99.34%
    Pirmenol ((±)-Pirmenol) hydrochloride is an orally active antiarrhythmic agent. Pirmenol hydrochloride inhibits IK.ACh (IC50: 0.1 μM) by blocking mAchR. Pirmenol hydrochloride can be used in the research of cardiovascular disease, such as atrial fibrillation.
    Pirmenol hydrochloride
  • HY-112598A
    PF-06815345 hydrochloride 2334434-49-8 98.15%
    PF-06815345 hydrochloride is an orally active and potent inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) with an IC50 value of 13.4 μM. PF-06815345 hydrochloride significantly decreases the PCSK9 level in vivo in mouse.
    PF-06815345 hydrochloride
  • HY-113341S
    7ß-Hydroxycholesterol-d7 349553-97-5
    7ß-Hydroxycholesterol-d7 is the deuterium labeled 7α-Hydroxycholesterol. 7β-Hydroxycholesterol is an oxysterol that derived by the oxidation of cholesterol. 7β-hydroxycholesterol can induce cellular oxidative stress, apoptosis, and necrosis, resulting in cytotoxicity. 7β-hydroxycholesterol has antitumor activity.
    7ß-Hydroxycholesterol-d7
  • HY-B0563S1
    Ropivacaine-d7 684647-62-9 99.38%
    Ropivacaine-d7 is deuterium labeled Ropivacaine. Ropivacain is a potent sodium channel blocker. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese[1][2]. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane[3]. Ropivacaine is used for the research of neuropathic pain management[1].
    Ropivacaine-d7
  • HY-W010144
    Phenidone 92-43-3 99.00%
    Phenidone, an orally active dual inhibitor of cyclooxygenase (COX) and lipoxygenase (LOX), ameliorates rat paralysis in experimental autoimmune encephalomyelitis. Phenidone is a potent hypotensive agent in the spontaneously hypertensive rat. Phenidone is used as a photographic developer.
    Phenidone
  • HY-W011114
    Clopidogrel-related Compound B hydrochloride 144750-52-7
    Clopidogrel-related Compound B hydrochloride is an impurity of Clopidogrel (HY-15283).
    Clopidogrel-related Compound B hydrochloride
  • HY-W011243
    11alpha-Hydroxyprogesterone 80-75-1 99.53%
    11alpha-Hydroxyprogesterone is the analogue of 11beta-Hydroxyprogesterone (HY-N2337), and can be used as an experimental control. 11beta-Hydroxyprogesterone is a potent inhibitors of 11β-Hydroxysteroid dehydrogenase; also activates human mineralocorticoid receptor in COS-7 cells with an ED50 of 10 nM.
    11alpha-Hydroxyprogesterone
  • HY-W050000
    OR-1855 101328-85-2 ≥98.0%
    OR-1855, an active metabolite of Levosimendan, has effect on human myometrial contractility. Levosimendan is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.
    OR-1855
Cat. No. Product Name / Synonyms Application Reactivity